Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK10 | P53779 | 12/20 | 0.77 |
| ▸ | MAPK9 | P45984 | 9/20 | 0.77 |
| ▸ | PTK2 | Q05397 | 5/20 | 0.62 |
| ▸ | PKMYT1 | Q99640 | 2/20 | 0.62 |
| ▸ | INSR | P06213 | 1/20 | 0.62 |
| ▸ | IGF1R | P08069 | 1/20 | 0.62 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.62 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.61 |
| ▸ | JAK2 | O60674 | 1/20 | 0.59 |
| ▸ | JAK1 | P23458 | 1/20 | 0.59 |
| ▸ | TYK2 | P29597 | 1/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.59 |
| ▸ | ULK1 | O75385 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3772335 | 0.90 | MAPK10 (0.77) | MAPK10MAPK9PTK2PKMYT1INSR | |
| SCHEMBL3767617 | 0.90 | MAPK10 (0.77) | MAPK10MAPK9PTK2PKMYT1INSR | |
| SCHEMBL1231775 | 0.87 | MAPK10 (1.00) | MAPK10MAPK9PTK2PKMYT1INSR | |
| SCHEMBL3770344 | 0.87 | MAPK10 (0.83) | MAPK10MAPK9PTK2PKMYT1INSR | |
| SCHEMBL1232329 | 0.81 | MAPK10 (0.85) | MAPK10MAPK9PTK2JAK2JAK1 | |
| SCHEMBL1231705 | 0.79 | MAPK10 (0.85) | MAPK10MAPK9PTK2JAK2JAK1 | |
| SCHEMBL12887657 | 0.79 | MAPK10 (0.85) | MAPK10MAPK9PTK2 | |
| SCHEMBL12886641 | 0.79 | MAPK10 (0.77) | MAPK10MAPK9JAK2JAK1TYK2 | |
| SCHEMBL12886573 | 0.78 | MAPK10 (0.53) | MAPK10MAPK9PTK2INSRIGF1R | |
| SCHEMBL11955700 | 0.78 | MAPK10 (0.70) | MAPK10MAPK9PTK2INSRIGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317663-A1 | ANILINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC | 2010-12-16 | — | — | US | disclosed |
| US-20100317663-A1 | ANILINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC | 2010-12-16 | — | — | US | disclosed |
| US-20100317663-A1 | ANILINOPYRIDINES AS INHIBITORS OF FAK | GLAXOSMITHKLINE LLC | 2010-12-16 | — | — | US | disclosed |
| WO-2009105498-A1 | ANILINOPYRIDINES AS INHIBITORS OF FAK | SMITHKLINE BEECHAM CORPORATION (US) | 2009-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317663-A1 | ANILINOPYRIDINES AS INHIBITORS OF FAK | PTK2, JAK2, SRC | MAPK10 386/4885MAPK9 173/4885PTK2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.